Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist?

Abstract

Widely regarded as safe and effective, PPIs are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute interstitial nephritis and subsequent large observational studies of AKI, CKD, and ESRD. The majority of studies showed higher risk of kidney outcomes among persons prescribed PPI medications, with effect sizes that were slightly higher for AKI (∼2- to 3-fold) compared with CKD and ESRD (1.2- to 1.8-fold). Although observational pharmacoepidemiology studies are limited by the possibility of residual confounding and confounding by indication, many of the described studies conducted rigorous sensitivity analyses aimed at minimizing these biases, including new-user design, comparison to similar agents (e.g., histamine2 receptor antagonists), and evaluation for a dose response, with robust results. Given the widespread use of PPIs, even a small effect on kidney outcomes could result in large public health burden. Timely cessation of PPI therapy when there is no clear indication for use might reduce the population burden of kidney disease.

Evaluation of Antiulcer Activity of 80% Methanol Extract and Solvent Fractions of the Root of Croton macrostachyus Hocsht: Ex Del. (Euphorbiaceae) in Rodents

“…Currently used antiulcer drugs cause adverse reactions, such as hypersensitivity, arrhythmia, impotence, gynecomastia, hematopoietic changes, and kidney disease [10,12].…”

Should we really STOP treating patients with IgA nephropathy with steroids?

“…Many physicians use long-term proton pump inhibitors to protect from the ulcerogenic effect of glucocorticoids. However, the prolonged use of these drugs may deteriorate renal function in some patients (35,38). Corticosteroids are metabolized by cytochrome P450 (CYP450) enzymes.…”

Renal Safety of Proton Pump Inhibitors

“…Y. Xie, также как и В. Lazarus, рекомендуют уделять строгое внимание контролю функции почек при применении ИПП. [52]. Авторы данного обзора проанали-зировали данные многочисленных обсервационных исследований, показав риск развития ОТИН и ХБП у больных, получающих различные ИПП.…”